Prediction of the course of Graves' disease after medical antithyroid treatment.
The course of thyrotoxicosis in 33 patients with Graves' disease was evaluated clinically and biochemically (free thyroxine index, serum triiodothyronine, thyroid stimulating antibodies, (TSAb), thyroid stimulating hormone binding inhibiting immunoglobulins (TBII)). Relapse of the disease was found to be correlated to anamnestic information of thyrotoxicosis among first degree relatives (predictive value 90%) and to concomitantly raised levels of TSAb and TBII at the start of treatment (predictive value 71%). Mean duration of treatment of patients with long-lasting remission was 16.8 months. When comparing various information used to predict relapse of Graves' disease, anamnestic information of familial predisposition to thyrotoxicosis carries the highest predictive value.
Eshøj
O
O
Kvetny
J
J
Mogensen
E F
EF
Bech
K
K
Bliddal
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D018828:Immunoglobulins, Thyroid-Stimulating; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000906:Antibodies; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating; D014284:Triiodothyronine; D008713:Methimazole; D013974:Thyroxine